Rapid Antibody Discovery Strategies to Support Optimized Next Generation Modalities
As novel and complex modalities beyond standard IgG antibodies continue to emerge, the need for large sets of molecularly-diverse, drug-quality leads with broad ranges of affinities is of increasing importance.
This presentation outlines strategies and technologies developed by AlivaMab Discovery Services (ADS) that enable discovery of large antibody panels with requisite properties to facilitate conversion into new modalities. Employing thoughtfully designed immunization strategies, deep sampling of the immunize repertoire and high throughput function-forward screening, ADS empowers partners with the antibody diversity and properties required to tackle the most challenging programs.
Watch this informative webinar and learn:
- Why new antibody therapeutic modalities - including multispecifics and antibody-drug conjugates (ADCs) - require larger sets of high-quality leads
- How screening strategies can be improved to include more translational assays earlier in the discovery process
- Techniques to generate a robust immune response and break tolerance
Complete the Form to Watch the Webinar
Presenter:
Dana Duey
Director, Antibody Discovery
AlivaMab Discovery Services